Clinical Trial Update: A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating drug-drug interaction between brigatinib and midazolam in ALK+ or ROS1+ solid tumors completed with posted results in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Brigatinib (brigatinib)
• Midazolam (Midazolam)

Snippet

Sponsor: Takeda | Conditions: Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2023-01-27